Study the Role of Serum visfatin in Type 2 Diabetic Patients with and without Hemodialysis

Abstract

Background: The incidence and prevalence of diabetes mellitus have grown significantly throughout the world, due primarily to the increase in type 2 diabetes. Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes mellitus (T₂DM), Visfatin has insulinomimetic effects by activating the insulin signal transduction pathway through binding to the same receptor. According our study have shown the relationship between visfatin a specific biomarker for T2DM without CKD and T2DM with CKD (hemodialysis).